stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Debt to equity
TG Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 1.2×, up 0.9× from fiscal 2025 (0.4×). Over the past ten years it has ranged from 0.0× (fiscal 2015) to 1.2× (fiscal 2022); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.4× | (65.51%) |
| FY2024 | 1.1× | 76.21% |
| FY2023 | 0.6× | (48.62%) |
| FY2022 | 1.2× | 324.99% |
| FY2021 | 0.3× | 356.39% |
| FY2020 | 0.1× | (92.15%) |
| FY2019 | 0.8× | 28,364.29% |
| FY2018 | 0.0× | 47.37% |
| FY2017 | 0.0× | 0.00% |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 1.2× | (3.44%) |
| Mar 2026 | 1.3× | 237.06% |
| Dec 2025 | 0.4× | (6.16%) |
| Sep 2025 | 0.4× | (54.42%) |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | −0.7× |
| CYTK Cytokinetics, Incorporated compare | −0.5× |
| KRYS Krystal Biotech, Inc. compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| SYRE Spyre Therapeutics, Inc. compare | 0.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 0.0× |
| TWST Twist Bioscience Corporation compare | 0.0× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.5× |
| TGTX TG Therapeutics, Inc. | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement